Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2018
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24625
- Acceso en línea:
- https://doi.org/10.1177/2055217317752202
https://repository.urosario.edu.co/handle/10336/24625
- Palabra clave:
- Medical and Health Sciences
Clinical Sciences
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_1989bc17e13602cf7cdd5d77356432d8 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/24625 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
3503d98b-87a6-4b47-8bfb-4acd1262e576-1193a5fdf-7195-4129-8398-3ef88ab2f369-10b96d002-3992-4ee1-8e90-e714a33c4e06-113bbdf66-c55d-4f9b-a6c0-aa1b900a9bb2-17ac36ac9-946b-40e6-8dd8-4012a9cea09e-109397e82-4de9-44ae-af1a-28e2608c9ccb-16379ef1c-371d-4a92-b2e7-4a74deaa9dff-179943239600799479176002020-06-11T13:20:54Z2020-06-11T13:20:54Z2018-01Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic infections including tuberculosis.Objective: The purpose of this study was to obtain consensus from a panel of neurologists, pulmonologists, infectious disease specialists, and epidemiology experts regarding the diagnosis, treatment, and monitoring of latent tuberculosis in patients with multiple sclerosis.Methods: A panel of experts in multiple sclerosis and tuberculosis was established. The methodological process was performed in three phases: definition of questions, answer using Delphi methodology, and the discussion of questions not agreed.Results: Tuberculosis screening is suggested when multiple sclerosis drugs are prescribed. The recommended tests for latent tuberculosis are tuberculin and interferon gamma release test. When an anti-tuberculosis treatment is indicated, monitoring should be performed to determine liver enzyme values with consideration of age as well as comorbid conditions such as a history of alcoholism, age, obesity, concomitant hepatotoxic drugs, and history of liver disease.Conclusion: Latent tuberculosis should be considered in patients with multiple sclerosis who are going to be treated with immunomodulatory and immunosuppressant medications. Transaminase level monitoring is required on a periodic basis depending on clinical and laboratory characteristics. In addition to the liver impairment, other side effects should be considered when Isoniazid is prescribed.application/pdfhttps://doi.org/10.1177/2055217317752202https://repository.urosario.edu.co/handle/10336/24625engMultiple Sclerosis Journal - Experimental Translational and ClinicalNo. 1Multiple Sclerosis Journal - Experimental Translational and ClinicalVol. 4Multiple Sclerosis Journal - Experimental Translational and Clinical, ISSN: , Vol.4, No.1 (2018-01); pp. 2055217317752202https://journals.sagepub.com/doi/pdf/10.1177/2055217317752202Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURMedical and Health SciencesClinical SciencesDiagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple SclerosisarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Navas, CarlosTorres-Duque, Carlos AMunoz-Ceron, JoeGarcía, Juan RZarco, LuisVélez, Lázaro AAwad, CarlosAlvarez, Carlos E.Castro, Carlos10336/24625oai:repository.urosario.edu.co:10336/246252021-06-03 00:50:31.248https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
title |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
spellingShingle |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis Medical and Health Sciences Clinical Sciences |
title_short |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
title_full |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
title_fullStr |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
title_full_unstemmed |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
title_sort |
Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis |
dc.subject.keyword.spa.fl_str_mv |
Medical and Health Sciences Clinical Sciences |
topic |
Medical and Health Sciences Clinical Sciences |
description |
Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic infections including tuberculosis.Objective: The purpose of this study was to obtain consensus from a panel of neurologists, pulmonologists, infectious disease specialists, and epidemiology experts regarding the diagnosis, treatment, and monitoring of latent tuberculosis in patients with multiple sclerosis.Methods: A panel of experts in multiple sclerosis and tuberculosis was established. The methodological process was performed in three phases: definition of questions, answer using Delphi methodology, and the discussion of questions not agreed.Results: Tuberculosis screening is suggested when multiple sclerosis drugs are prescribed. The recommended tests for latent tuberculosis are tuberculin and interferon gamma release test. When an anti-tuberculosis treatment is indicated, monitoring should be performed to determine liver enzyme values with consideration of age as well as comorbid conditions such as a history of alcoholism, age, obesity, concomitant hepatotoxic drugs, and history of liver disease.Conclusion: Latent tuberculosis should be considered in patients with multiple sclerosis who are going to be treated with immunomodulatory and immunosuppressant medications. Transaminase level monitoring is required on a periodic basis depending on clinical and laboratory characteristics. In addition to the liver impairment, other side effects should be considered when Isoniazid is prescribed. |
publishDate |
2018 |
dc.date.created.spa.fl_str_mv |
2018-01 |
dc.date.accessioned.none.fl_str_mv |
2020-06-11T13:20:54Z |
dc.date.available.none.fl_str_mv |
2020-06-11T13:20:54Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1177/2055217317752202 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/24625 |
url |
https://doi.org/10.1177/2055217317752202 https://repository.urosario.edu.co/handle/10336/24625 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.citationIssue.none.fl_str_mv |
No. 1 |
dc.relation.citationTitle.none.fl_str_mv |
Multiple Sclerosis Journal - Experimental Translational and Clinical |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 4 |
dc.relation.ispartof.spa.fl_str_mv |
Multiple Sclerosis Journal - Experimental Translational and Clinical, ISSN: , Vol.4, No.1 (2018-01); pp. 2055217317752202 |
dc.relation.uri.spa.fl_str_mv |
https://journals.sagepub.com/doi/pdf/10.1177/2055217317752202 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Multiple Sclerosis Journal - Experimental Translational and Clinical |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1818106681150668800 |